A British health charity has warned people with epilepsy against using CBD products that do not have a pharmaceutical licence.
Epilepsy Research UK, a national organisation which funds research, says that “whilst there is evidence that medical-grade preparations of an active ingredient of cannabis, cannabidiol, can be beneficial in some types of epilepsy, cannabis oil itself cannot be considered a safe or effective treatment. This is due to the variety of compounds found in over-the-counter cannabis oils, some of which may have harmful effects.”
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.
Regulatory report: medical and recreational cannabis – a global overview
CBD-Intel has compiled and classified the regulatory data on medical and recreational cannabis in 50 jurisdictions around the world.
The report, accompanied by a more detailed database, provides an overview of the regulatory situation in the selected countries using maps, and assesses the likelihood that the status quo may change in the future.